SQZ Biotechnologies (SQZB) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.04
• 52-Week Range: $0.02 to $0.12
• Volume: N/A
• Average Volume: 4,267 shs
• Market Capitalization: $825,720.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZB Stock Analysis - Frequently Asked Questions

How have SQZB shares performed this year?

SQZ Biotechnologies' stock was trading at $0.03 at the beginning of the year. Since then, SQZB stock has decreased by 6.7% and is now trading at $0.0280.
View the best growth stocks for 2025 here.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SQZ Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

• Today: 5/25/2025
• Next Earnings (Estimated): 5/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SQZB
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $21.48 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 29,490,000
• Free Float: 24,772,000
• Market Cap: $825,720.00
• Optionable: N/A
• Beta: 1.40